Kodiak Sciences Inc. (KOD)
KOD Stock Up 24% in 3 Months: Here's What You Need to Know
Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.
Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)
Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock
Jefferies has upgraded Kodiak Sciences Inc. KOD, a biopharmaceutical company focused on retinal (eye) diseases.
